- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Novo Nordisk diabetes drug Ozempic back on shelves in US after months of shortage
![Novo Nordisk diabetes drug Ozempic back on shelves in US after months of shortage Novo Nordisk diabetes drug Ozempic back on shelves in US after months of shortage](https://medicaldialogues.in/h-upload/2023/01/11/750x450_197403-novo-nordisk.webp)
US: Novo Nordisk's best-selling diabetes treatment drug Ozempic is back on the shelves in the United States after months of shortage, the U.S. Food and Drug Administration (FDA) website showed on Friday.
The main active ingredient in Ozempic is semaglutide, also the key ingredient in Novo's obesity drug Wegovy, which has been seeing supply shortage due to high demand.
The company said the 0.25 mg, 0.5 mg and the 1 mg doses of Ozempic are available for patients. The 2 mg dose, however, has limited availability until the end of this month, largely due to the demand coupled with overall global supply constraints.
"While product continues to be manufactured and shipped, patients in some areas of the country will experience delays with the 2mg dose," Novo Nordisk said.
Read also: Novo Nordisk to cut US list prices for several insulin products by up to 75 percent next year
In February, the company had warned of supply constraints this year on Ozempic. The drug recorded sales of 59.75 billion Danish crowns ($8.56 billion) in 2022.
Ozempic's demand was also seen to be partly driven by prescriptions to non-diabetic patients seeking to lose weight, which is outside the drug's approved indication
Read also: Continue CT with 30 ongoing Indian subjects: CDSCO panel tells Novo-Nordisk on Insulin Icodec
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751